Endoscopic Sleeve Gastroplasty + Fundal Mucosal Ablation for Obesity

This trial explores a new method to help people with obesity lose weight. It tests whether adding fundal mucosal ablation (FMA) to endoscopic sleeve gastroplasty (ESG), a procedure that reduces stomach size, can enhance weight loss and increase feelings of fullness. Individuals with a BMI of 30 or more who have struggled with weight loss through diet or exercise may be suitable candidates. Participants will receive either the combined ESG and FMA treatment or ESG alone to compare results. The main goal is to determine which approach leads to better weight loss and health improvements over a year. As an unphased trial, this study offers participants the chance to contribute to innovative obesity treatments and potentially improve their own health outcomes.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Research has shown that both treatments in this trial have strong safety records. Endoscopic Sleeve Gastroplasty (ESG) has been studied with many participants, and results indicate that ESG effectively treats obesity with a low rate of serious side effects, between 1.4% and 2.3%. This procedure is not surgery and is associated with long-term weight loss.

Fundal Mucosal Ablation (FMA) uses a method called Hybrid Argon Plasma Coagulation to help reduce hunger. Studies suggest that FMA is safe, with most patients experiencing only mild, short-term discomfort. Past research has combined this procedure with ESG, demonstrating it as a safe addition.

Researchers are excited about these treatments because they offer a less invasive option for tackling obesity. Endoscopic Sleeve Gastroplasty (ESG) alone is already a minimally invasive procedure that reduces the size of the stomach without the need for surgery, which can mean fewer complications and faster recovery compared to traditional bariatric surgeries like gastric bypass. The addition of Fundal Mucosal Ablation to ESG is particularly intriguing as it may enhance weight loss results by targeting the stomach lining to further influence hunger hormones. This combination has the potential to provide a powerful, non-surgical alternative for individuals struggling with obesity, offering a potentially quicker path to weight loss with reduced risk.

Research has shown that Endoscopic Sleeve Gastroplasty (ESG), which participants in this trial may receive, can lead to significant weight loss. Patients typically lose 15% to 20% of their body weight within 12 to 24 months. Many also experience improvements in obesity-related conditions, such as high blood pressure and type 2 diabetes. Studies indicate that ESG is safe and effective, with lasting results when combined with lifestyle changes.